P22 Telehealth during Covid-19: patient satisfaction of virtual training on the MiniMed 670G System in people with type 1 diabetes
DOI:
https://doi.org/10.47196/diab.v54i3Sup.406Keywords:
COVID-19, virtual training, type 1 diabetesAbstract
Background: the coronavirus disease (COVID-19) pandemic has challenged the ability to do face-to-face training on advanced diabetes management technologies. Like in United States and Latinamerica, in Argentina, Medtronic Diabetes shifted from occasional to 100% virtual training on all diabetes devices in mid-March 2020.
Aim: to evaluate patient satisfaction of virtual training on the MiniMed™ 670 G hybrid closed-loop system in type 1 diabetes.
Methods: from February to April 2020 training on the MiniMed™ 670G system was 90% completed using online platform. Virtual training satisfaction was capture through online surveys at the end of follow up (90 days). Patient satisfaction was determined by Net Promotor Score (NPS®). Continuous glucose monitoring (CGM) results were measured using the CareLink Personal database.
Results: between February to Abril 2020 included 31 children and adults (age: 31.4 ± 15.1 years, range 9 - 57) previous use of SAP-PLGS 71%, baseline HbA1c 7.4 ± 1% and Time in Range (TIR) between 70-180 mg/dl 65.9%. Virtual training and follow up were evaluate: 87% “very satisfied”, 13% “satisfied”. The NPS® was 87%. The participants used the sensor for a median of 88.7% (±16.8) of the time and spent a median of 91.1% (±10) in Auto Mode at the end of the follow up. Frequency of downloads data by CareLink™ Personal was one/twice a week in 87% patients. Time in range (TIR) between 70-180 mg/dl significantly increased from 65.9% at baseline to 76% at follow up (p=0,001).
Conclusions: high patient satisfaction levels, supports the use of virtual methodology for the training of new patients on advanced diabetes management technologies.
Downloads
Published
How to Cite
Issue
Section
License
![Creative Commons License](http://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.